Skip to content
Aussie8 – Lifestyle
Author:
ITM Isotope Technologies Munich SE
ITM to Announce Quality of Life Data from the Phase 3 COMPETE Trial in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at ASCO 2026
April 21, 2026
←
Previous Page
1
2